Medication Overview

Taltz (ixekizumab) is an injectable prescription medication used primarily to treat moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting interleukin-17A (IL-17A), a cytokine that plays a key role in driving inflammation associated with these conditions.

Who Should Consider Taltz? Taltz is suitable for adults who:

  • Have moderate to severe plaque psoriasis and are candidates for systemic therapy or phototherapy.
  • Suffer from active psoriatic arthritis.
  • Are diagnosed with active ankylosing spondylitis.

How is Taltz Administered? Taltz is administered as a subcutaneous injection. The typical regimen includes an initial loading dose followed by subsequent doses every 4 weeks. Patients are usually trained by healthcare professionals on how to self-administer using a pre-filled syringe or auto-injector.

Important Information for Taltz Users:

  • How to Use: Follow your healthcare provider’s instructions for self-administering Taltz injections.
  • Storage: Store Taltz in the refrigerator. Allow the medication to reach room temperature before injecting to minimize discomfort.
  • Side Effects: Common side effects include injection site reactions, upper respiratory infections, and fungal infections. Serious side effects can include severe allergic reactions and inflammatory bowel disease. Report any severe or unusual symptoms to your healthcare provider.
  • Monitoring: Regular medical check-ups and possibly lab tests are recommended to monitor your health and the medication’s effectiveness.

Medication Warnings

  • Infections: Taltz can weaken the immune system, increasing the risk of serious infections. Promptly report any signs of infection, such as fever, chills, or persistent cough, to your healthcare provider.
  • Allergic Reactions: Seek immediate medical help if you experience symptoms like rash, hives, swelling of the face, or difficulty breathing.
  • Inflammatory Bowel Disease: Taltz may cause new or worsening symptoms of inflammatory bowel disease. Report any new or worsening stomach pain or diarrhea.
  • Vaccinations: Avoid live vaccines during treatment with Taltz. Discuss your vaccination history with your healthcare provider.

Who Should and Shouldn’t Take Taltz?

  • Suitable Candidates:
    • Adults with moderate to severe plaque psoriasis, active psoriatic arthritis, or ankylosing spondylitis who require targeted immunomodulatory treatment.
  • Unsuitable Candidates:
    • Individuals with severe, active infections.
    • Patients with known hypersensitivity to ixekizumab or any components of the product.
    • Those with a history of inflammatory bowel disease, unless closely monitored by a healthcare provider.

For more detailed information and personalized advice, consult your healthcare provider.